BR112019015721A2 - Inibidores de tiol isomerases e uso dos mesmos - Google Patents

Inibidores de tiol isomerases e uso dos mesmos Download PDF

Info

Publication number
BR112019015721A2
BR112019015721A2 BR112019015721-2A BR112019015721A BR112019015721A2 BR 112019015721 A2 BR112019015721 A2 BR 112019015721A2 BR 112019015721 A BR112019015721 A BR 112019015721A BR 112019015721 A2 BR112019015721 A2 BR 112019015721A2
Authority
BR
Brazil
Prior art keywords
disease
zafirlukast
isomerase
extracellular
thiol
Prior art date
Application number
BR112019015721-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Kennedy Daniel
Gibbins Jonathan
Holbrook Lisa-Marie
Original Assignee
Western New England University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Western New England University filed Critical Western New England University
Publication of BR112019015721A2 publication Critical patent/BR112019015721A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112019015721-2A 2017-01-30 2018-01-29 Inibidores de tiol isomerases e uso dos mesmos BR112019015721A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762451858P 2017-01-30 2017-01-30
US62/451,858 2017-01-30
PCT/US2018/015694 WO2018140858A1 (en) 2017-01-30 2018-01-29 Thiol isomerases inhibitors and use thereof

Publications (1)

Publication Number Publication Date
BR112019015721A2 true BR112019015721A2 (pt) 2020-03-24

Family

ID=62978426

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019015721-2A BR112019015721A2 (pt) 2017-01-30 2018-01-29 Inibidores de tiol isomerases e uso dos mesmos

Country Status (6)

Country Link
US (2) US11872210B2 (https=)
EP (1) EP3585809B1 (https=)
JP (3) JP7272655B2 (https=)
BR (1) BR112019015721A2 (https=)
CA (2) CA3052071A1 (https=)
WO (1) WO2018140858A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019164874A1 (en) 2018-02-20 2019-08-29 Western New England University Thiol isomerases inhibitors for the treatment and prevention of food allergies, allergic diseases, and inflammatory diseases
CN113289020B (zh) * 2021-05-17 2023-04-18 福州大学 蛋白质二硫键异构酶小分子抑制剂及其应用
CA3219671A1 (en) 2021-05-19 2022-11-24 Thomas Christian Lines Quercetin-containing compositions for use in treating amyotrophic lateral sclerosis
EP4518852A1 (en) * 2022-05-06 2025-03-12 Quercis Pharma AG Method for treating cancers and neurological diseases using quercetin-containing compositions
WO2024039822A1 (en) * 2022-08-19 2024-02-22 Western New England University Thiol isomerases inhibitors; preparation thereof; and methods of use thereof
WO2025094946A1 (ja) * 2023-10-30 2025-05-08 国立大学法人東海国立大学機構 抗体又はその抗原結合性断片、がんの治療用キット、及びがんの治療用組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA825413B (en) 1981-08-26 1983-06-29 Pfizer Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
US4985465A (en) 1989-07-14 1991-01-15 Hendler Sheldon S Method for inhibiting viral and retroviral infections
US5565473A (en) 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
GB9027018D0 (en) 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds
GB9723985D0 (en) 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
IL139243A0 (en) * 2000-10-24 2001-11-25 Internat Specialty Products Is Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof
DK1817301T3 (da) * 2004-11-22 2012-02-27 Lilly Co Eli Forstærkere af glutamat-receptorer
KR100649009B1 (ko) 2004-12-30 2006-11-27 동부일렉트로닉스 주식회사 시모스 이미지 센서의 광감지 소자 및 그의 제조방법
WO2006127525A2 (en) 2005-05-20 2006-11-30 Jack Arbiser Proteasome inhibitors and uses thereof
US8337814B2 (en) 2005-12-15 2012-12-25 Topical Sinus Therapeutics, Inc. Treatment of active infections, sinusitis, rhinitis, and related neurological disorders and related compositions
WO2008033466A2 (en) 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
US8058243B2 (en) 2006-10-13 2011-11-15 Hsc Research And Development Limited Partnership Method for treating a brain cancer with ifenprodil
DE102007001804A1 (de) 2007-01-12 2008-07-17 Johann Wolfgang Goethe-Universität Frankfurt am Main Verwendung von GABAB-Rezeptor selektiven Agonisten zur Behandlung entzündlicher Hauterkrankungen
EP2269076A4 (en) 2008-03-14 2011-04-06 Nat Jewish Health METHOD FOR DETERMINING THE RECOMMENDATION FOR TREATMENT WITH LEUKOTRIA MODIFIERS
US8980917B2 (en) 2008-06-12 2015-03-17 The Johns Hopkins University Methods for treating or preventing brain infections
WO2013055674A1 (en) 2011-10-10 2013-04-18 The University Of Toledo Method for treating infections
SG11201406142XA (en) 2012-03-27 2014-10-30 Univ Duke Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
CN103505731A (zh) 2012-06-15 2014-01-15 中国药科大学 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途
CA2901413A1 (en) 2013-03-13 2014-10-09 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of vasculitis
US9616056B2 (en) 2013-03-15 2017-04-11 Institute For Cancer Research Inhibition of leukotriene synthesis and activity in the treatment of sonic hedgehog-associated medulloblastoma
RU2667644C2 (ru) * 2013-04-22 2018-09-21 Тотиги Инститьют Оф Клиникал Патолоджи Противоопухолевое средство
US20160145209A1 (en) * 2013-06-21 2016-05-26 The Broad Institute, Inc. Compounds and compounds for use in methods for treating diseases or conditions mediated by protein disulfide isomerase
GB201321089D0 (en) 2013-11-29 2014-01-15 Univ East London Leukotriene receptor antagonists and their derivatives for use as antibacterial agents
WO2016118639A1 (en) * 2015-01-20 2016-07-28 The Trustees Of Columbia University In The City Of New York Small molecule oxidizers of pdi and their use
JP6528314B2 (ja) * 2015-03-20 2019-06-12 国立大学法人山口大学 Ａ（Ｈ１Ｎ１）ｐｄｍ０９インフルエンザウイルス感染による気管支喘息の予防又は改善剤

Also Published As

Publication number Publication date
US20210008032A1 (en) 2021-01-14
JP7272655B2 (ja) 2023-05-12
EP3585809B1 (en) 2025-07-02
EP3585809A1 (en) 2020-01-01
JP2020514411A (ja) 2020-05-21
CA3052071A1 (en) 2018-08-02
JP2024161023A (ja) 2024-11-15
WO2018140858A1 (en) 2018-08-02
CA3282526A1 (en) 2025-10-30
EP3585809A4 (en) 2021-02-24
US20240108600A1 (en) 2024-04-04
US11872210B2 (en) 2024-01-16
JP2023030014A (ja) 2023-03-07

Similar Documents

Publication Publication Date Title
BR112019015721A2 (pt) Inibidores de tiol isomerases e uso dos mesmos
US20230142627A1 (en) Pharmaceutical compositions and methods
Jang et al. Hydrogen sulfide treatment induces angiogenesis after cerebral ischemia
CA3183081A1 (en) Combination therapy for treatment of cancer
JP2014058561A (ja) 癌を処置するための治療剤の組合せ
MX2011005667A (es) Combinacion farmaceutica que comprende un inhibidor de hsp90 y un inhibidor de mtor.
Liu et al. Morroniside enhances angiogenesis and improves cardiac function following acute myocardial infarction in rats
US20250388633A1 (en) Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
KR20220131224A (ko) 허혈-재관류 손상 및/또는 폐 손상을 치료하기 위한 화합물, 조성물 및 방법
US12168019B1 (en) 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression
KR101497868B1 (ko) 리모닌을 유효성분으로 포함하는 혈관근육세포의 증식과 관련된 질환의 예방 및 치료용 약제학적 조성물
US20190290729A1 (en) Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
US20210317070A1 (en) Cannabidiol derivatives as inhibitors of the hif prolyl hydroxylases activity
WO2017046229A1 (en) Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
KR101599259B1 (ko) 혈관 신생작용 관련 질환 치료를 위한 HIF-1α 저해 화합물
Imtiaz et al. Selection of lansoprazole from an
WO2025019473A1 (en) Isoxazole-3-carboxyamide compounds for enhancing telomerase reverse transcriptase (tert) expression
US20250120956A1 (en) Azole Compounds for Enhancing Telomerase Reverse Transcriptase (TERT) Expression
HK40091747A (zh) 用於治疗癌症的组合疗法
CN107397749A (zh) 莲花掌苷的新用途
Uppala et al. Antiretroviral Therapy: What to Look Out For!
US20160128999A1 (en) Masitinib for treating hepatic cancer
EP3400233A1 (en) Pharmaceutical compositions and methods
KR20160096842A (ko) Ｍａｚ５１을 포함하는 신경아교종 치료용 약학조성물

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]